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Huntington’s Disease (HD) is the most frequent neurodegenerative disease caused by an
expansion of polyglutamines (CAG).The main clinical manifestations of HD are chorea, cog-
nitive impairment, and psychiatric disorders.The transmission of HD is autosomal dominant
with a complete penetrance. HD has a single genetic cause, a well-deﬁned neuropathol-
ogy, and informative pre-manifest genetic testing of the disease is available. Striatal atrophy
begins as early as 15 years before disease onset and continues throughout the period of
manifest illness.Therefore, patients could theoretically beneﬁt from therapy at early stages
of the disease. One important characteristic of HD is the striatal vulnerability to neurode-
generation, despite similar expression of the protein in other brain areas. Aggregation of the
mutated Huntingtin (HTT), impaired axonal transport, excitotoxicity, transcriptional dysreg-
ulation as well as mitochondrial dysfunction, and energy deﬁcits, are all part of the cellular
events that underlie neuronal dysfunction and striatal death. Among these non-exclusive
mechanisms, an alteration of striatal signaling is thought to orchestrate the downstream
events involved in the cascade of striatal dysfunction.
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CLINICAL ASPECTS
Huntington’s disease (HD) is a fatal disorder with a general preva-
lence of about 10 per 100,000 births, with some regions of the
world having a higher prevalence of up to 700 per 100,000 (Harper,
1992; Paradisi et al., 2008). The typical age of onset is usually
between 35 and 50 years but is very variable ranging from 1 to
85 years or more. The disease begins before 30 years of age in
about 15% of patients and is then referred to as juvenile HD.
The duration of the disease from onset to death is about 15–
20 years. Clinical features of HD can be divided into three groups:
movement disorders, cognitive impairment, and psychiatric man-
ifestations. Chorea is the most characteristic movement disorder
of classical HD and is characterized by brief, involuntary, abnor-
mal movements, which appear unpredictably in all the parts of
the body (Quinn and Schrag, 1998). As the disease progresses, the
choreic movements generally tend to diminish and be replaced by
akineto-rigid parkinsonism that can be associated with dystonic
postures (Penney et al., 1990; Kremer et al., 1992). At an advanced
stage of the disease, a high proportion of HD patients have falls
(Busse et al., 2009), and a loss of independent ambulation, which
may precipitate admission to nursing homes (Wheelock et al.,
2003). Other movement disorders can be occasionally observed
during the course of the disease, including tics (Kerbeshian et al.,
1991; Jankovic et al., 1995) and myoclonia (Vogel et al., 1991;
Carella et al., 1993; Thompson et al., 1994). Cognitive impairment
plays a major role in the functional decline and loss of autonomy
of the patients. It can precede motor symptoms or occur during
the course of the disease, and usually leads, in turn, to dementia.
Cognitive alteration has a sub-cortical proﬁle with predominant
impairment of executive/attention functions (Caine et al., 1978;
Bamford et al., 1995; Ho et al., 2003; Peinemann et al., 2005).
Instrumental functions (language, praxia, and gnosis) and mem-
ory are generally better preserved in HD than in other types of
dementia (Caine et al., 1977; Hodges et al., 1990; Pillon et al.,
1993, 1994). Neurobehavioral symptoms are very frequent. They
can be the initial manifestations of the disease or occur at any
time during the course of the disease (Shiwach andNorbury, 1994;
Kirkwood et al., 2002). Irritability, agitation, apathy, anxiety, social
withdrawal, impulsiveness, alcohol abuse, obsessive–compulsive
disorder (Cummings and Cunningham, 1992; Patzold and Brune,
2002), hostility, and sexual disorders are common (Pﬂanz et al.,
1991; Fedoroff et al., 1994; Paulsen et al., 2001).Mooddisorders are
very frequent along HD, including depression (Caine and Shoul-
son, 1983; Folstein et al., 1983; Di Maio et al., 1993; Cummings,
1995; Jensen et al., 1998) and manic episodes (Mendez, 2000).
Various types of psychotic disorders can also be observed (Cum-
mings, 1995; Rosenblatt and Leroi, 2000). HD patients have a risk
of suicide that is 10 times higher than in the general population.
Sleep disorders and weight loss are also frequently encountered in
HD patients (Morton et al., 2005; Arnulf et al., 2008; Aziz et al.,
2008; Videnovic et al., 2009).
Contrary to patients with typical HD, those with the juve-
nile form (or the Westphal variant) do not display chorea.
These forms are characterized by a combination of progressive
akineto-rigid parkinsonism, dystonia, ataxia, dementia, and psy-
chiatric disorders (Siesling et al., 1997; Gonzalez-Alegre and Aﬁﬁ,
2006). Seizures can also occur. Patients with childhood-onset HD
can develop non-speciﬁc encephalopathy resulting in seizures,
myoclonus, and rapid cognitive deterioration (Siesling et al., 1997;
Gambardella et al., 2001; Gonzalez-Alegre and Aﬁﬁ, 2006).
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GENETICS
The mutation responsible for HD is located at the 5′ terminal part
of the HTT gene on chromosome 4p16.3 (The Huntington Col-
laborative Research Group, 1993). The mutation consists of an
unstable expansion of the CAG repeat sequence, located in exon
1, at the NH2-terminal part of the protein. The mutated pro-
tein causes neuronal dysfunction and death, particularly in the
striatum and cortex, although it is ubiquitously expressed. The
penetrance of the mutation is almost complete. The HTT gene
is normal when it contains less than 27 CAG repeats. Between 27
and 35 CAG repeats do not cause HD but may expand in succes-
sive generations. Intermediate alleles (between 36 and 39 repeats)
repetitions are usually associated with late onset disease and may
express a variable penetrance as the patient may die before disease
onset. Individuals with 39 CAG repeats or greater will develop
symptoms of HD (Kenney et al., 2007; Reynolds, 2008; Semaka
et al., 2008). About 10% of HD patients have no family history
of HD (Goldberg et al., 1993; Davis et al., 1994), with some of
these patients receiving the mutant allele from an asymptomatic
father with an intermediate allele. Such alleles do not cause HD
but show instability on replication and tend to expand in succes-
sive generation with greater instability in spermatogenesis than in
oogenesis (Zuhlke et al., 1993; Ranen et al., 1995). This instability
of increased number of CAG repeats over successive generations
explains the phenomenon of genetic anticipation,which is deﬁned
by the tendency of an earlier disease onset in successive genera-
tions (Goldberg et al., 1993; Myers et al., 1993; Alford et al., 1996).
The age of onset cannot be predicted from the CAG repeat length
in clinical practice. However, the number of repeats inversely cor-
relates with the age of onset (Andrew et al., 1993; Duyao et al.,
1993; Snell et al., 1993; Wexler et al., 2004; Andresen et al., 2007).
NEUROPATHOLOGY
Brain weight may be reduced by as much as 25–30% in advanced
HD cases. Gross pathology of HD is limited to the brain, with
atrophy predominating in the caudate–putamen and to a lesser
extent, the cerebral cortex. The neuropathological signature of HD
is the prominent striatal neuron loss and the presence of intranu-
clear inclusion bodies, which mainly consist of the accumula-
tion of abnormal expansion of polyglutamines [Exp-Huntingtin
(HTT)]. A grading system for the striatal neuropathology was
established using macroscopic and microscopic criteria (Vonsat-
tel’s grade; Vonsattel et al., 1985). It deﬁnes ﬁve grades ranging
from 0 to 4 with increasing severity. The grade correlates closely
with the extent of clinical disability. The most vulnerable neu-
ronal population is the medium spiny neurons (MSNs) of the
striatum. According to the Vonsattel’s grade, the striato-pallidal
MSNs, which express enkephalin and dopaminergic D2 recep-
tors, degenerate ﬁrst (grade 2). Then striato-nigral MSNs which
express substance P and dopaminergic D1 receptors degenerate
(grade 3). The degeneration of MSNs occurs according to a dorso-
ventral andmedio-lateral gradient and is associatedwith a reduced
expression of substance P, leu-enkephalin, calcineurin, calbindin,
histamine H2-receptors, dopamine receptors, cannabinoid recep-
tors, and Adenosine A2 receptors (Goto et al., 1989; Martinez-Mir
et al., 1991; Richﬁeld et al., 1991; Richﬁeld and Herkenham,
1994). The striatal interneurons, aspiny striatal cholinergic, and
somatostatine containing neurons, are relatively spared (Lange
et al., 1976; Dawbarn et al., 1985; Ferrante et al., 1985, 1987, 1991).
Another characteristic neuropathological change is a modiﬁcation
of the dendritic arborization of spiny neurons, with an axonal
retraction before cell death (Graveland et al., 1985; Kiechle et al.,
2002).
MOLECULAR MECHANISMS OF THE DISEASE
Whether neuronal degeneration in HD is due to the loss of nor-
mal HTT properties or a gain of toxic functions, or both, is
not fully elucidated. In addition, age-related “normal” alterations
in cellular functioning may accelerate HD pathogenesis (Diguet
et al., 2009). Importantly, HTT is required for normal embry-
onic development as the loss of the protein leads to lethality of
mouse embryos around day 8.5 (Duyao et al., 1995; Zeitlin et al.,
1995) and the selective knockdown of the protein in neurons and
testis produces apoptosis in these tissues (Dragatsis et al., 2000).
The wild-type HTT is a ubiquitous protein, expressed in most
cells of the organism and within virtually all cellular compart-
ments (DiFiglia et al., 1997; Gutekunst et al., 1999; Kegel et al.,
2002, 2005; Hoffner et al., 2005; Caviston et al., 2007; Rockabrand
et al., 2007; Strehlow et al., 2007). Cell-based assays have focused
on striatal speciﬁc cell-autonomous effects of Exp-HTT on HD
neuropathology, since striatal but not cortical neurons in culture,
show spontaneous degeneration in presence of Exp-HTT (Saudou
et al., 1998; Arrasate et al., 2004; Garcia et al., 2004). Evidence in
favor of cell-autonomous effects also include that a lentiviralmedi-
ated delivery of Exp-HTT to rat striatum results in a progressive
pathology characterized by the appearance of ubiquitinated HTT
aggregates, loss of dopamine- and cAMP-regulated phosphopro-
tein of 32 kDa (DARPP-32) staining, and cell death (De Almeida
et al., 2002). Nevertheless, in a genetic model with striatal speciﬁc
expression of Exp-HTT, cell-autonomous nuclear accumulation
of Exp-HTT aggregates in striatal neurons were observed, but no
signiﬁcant locomotor deﬁcits nor striatal neuropathology, were
found (Gu et al., 2007). This work suggested a“two-hit”hypothesis
in which both cell-autonomous toxicity and pathological cell–cell
interactions are critical to HD pathogenesis.
Huntingtin has multiple interacting partners, some of them
exhibiting enhanced binding with Exp-HTT, while a handful pre-
fer associating with the wild-type HTT (Harjes and Wanker, 2003;
Li and Li, 2004). Among the binding partners of HTT are a dozen
transcription factors which appear to affect the transcriptional
proﬁle in HD brain tissue or cells (Luthi-Carter et al., 2000, 2002;
Sipione et al., 2002; Sugars and Rubinsztein, 2003; Zhai et al.,
2005; Kuhn et al., 2007). HTT is also considered as a scaffold pro-
tein, orchestrating the intracellular trafﬁcking, signaling pathways,
and transcriptional activity that are required for neuronal home-
ostasis; these functions being strongly hindered by the Exp-HTT
expression (see below). Exp-HTT is cleaved by various intracel-
lular proteases, including caspases, and this proteolytic processing
plays a key role in the pathophysiology of HD since the cleaved N-
terminal fragment is much more toxic than the full-length mutant
protein. These cleaved versions of Exp-HTT can also undergo
aggregate formation (Scherzinger et al., 1997; Huang et al., 1998;
Perutz et al., 2002), which is thought to interfere with normal cel-
lular functioning.Aggregates of insoluble proteins are found in the
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brain of HDpatients and in variousHDmodels. They are enriched
in striatal neurons and ﬁrst appear in the neuropil of striatalMSNs
(Li et al., 2000, 2001; Lee et al., 2004). By sequestering thewild-type
HTT (Martindale et al., 1998) or associated proteins involved in
transcription (Kazantsev et al., 1999; Steffan et al., 2000; Nucifora
et al., 2001) or transport (Gunawardena et al., 2003; Trushina et al.,
2004), these aggregates are thought to alter the fate of neuronal
cells. Aggregate-mediated toxicity could be attributed to defects in
RNA synthesis, cell survival, microtubule-dependent trafﬁcking,
or the ubiquitin–proteasome system (DiFiglia et al., 1997; Harjes
and Wanker, 2003; Li and Li, 2004; Bennett et al., 2007). Never-
theless, the toxicity of aggregates still remains an issue of debate.
Several studies have indicated that Exp-HTT aggregates are con-
nected with neurodegeneration or cytotoxicity (Davies et al., 1997;
DiFiglia et al., 1997; Ordway et al., 1997), whereas other studies
have suggested that aggregate formation is either not intimately
correlated with cytotoxicity (Saudou et al., 1998; Arrasate et al.,
2004; Slow et al., 2005; Sawada et al., 2007; Mitra et al., 2009) or
plays a protective role in cells (Arrasate et al., 2004; Mitra et al.,
2009). Some authors argue that smaller oligomeric aggregates may
be more toxic than larger ones (Gong et al., 2008). Furthermore,
Exp-HTT can misfold into distinct β-sheet aggregates, called amy-
loids, which can be either toxic or non-toxic depending on their
conformation (Nekooki-Machida et al., 2009). Aggregate toxicity
can also depend on the cellular compartment in which they are
localized, for example they could be more toxic in the neurites
than in the nucleus (Li et al., 2000, 2001; Lee et al., 2004). Impor-
tantly, aggregates cannot be cleared by the ubiquitin–proteasome
system (Bence et al., 2001; Jana et al., 2001; Verhoef et al., 2002;
Venkatraman et al., 2004) and alter the normal efﬁcacy of the
clearance-machinery (Bennett et al., 2007; Hunter et al., 2007).
The lower basal activity of the ubiquitin–proteasome system in
neurons as compared to glial cells may account for the preferential
accumulation of aggregates in neurons (Tydlacka et al., 2008). It is
noteworthy that inhibiting the aggregation of Exp-HTT can alle-
viate the symptoms in various models of HD (Carmichael et al.,
2000; Jana et al., 2000; Vacher et al., 2005; Ravikumar et al., 2006;
Chopra et al., 2007; Herbst and Wanker, 2007; Perrin et al., 2007;
Sarkar et al., 2007; Seo et al., 2007).
CHANGES IN AXONAL TRANSPORT AND SYNAPTIC
DYSFUNCTION
Vesicular transport is altered in HD and is linked to a subsequent
synaptic dysfunction (Gunawardena et al., 2003; Szebenyi et al.,
2003; Gauthier et al., 2004; Trushina et al., 2004; Caviston and
Holzbaur, 2009; Sinadinos et al., 2009). These defaults of trafﬁck-
ing are mainly due to an impaired interaction between Exp-HTT
and motor proteins (Szebenyi et al., 2003; Lee et al., 2004), but
can also be a consequence of neuritic aggregates that act as phys-
ical roadblocks (Gunawardena et al., 2003; Szebenyi et al., 2003;
Trushina et al., 2004). According to the non-autonomous theory,
the“neurotrophindisorderhypothesis”is themostwidely accepted
(Zuccato and Cattaneo, 2009). The release of brain derived neu-
rotrophic factor (BDNF) from cortical afferences, which provides
an important neurotrophic support to striatal neurons, is impaired
in HD. Transcriptional dysregulation of BDNF in cortical neu-
rons was ﬁrst described (Zuccato et al., 2001; see Transcriptional
Dysregulation chapter below). Then, altered axonal transport
deﬁcit of BDNF from cortical neurons, was shown to participate
in the default of BDNF release in the striatum (Gauthier et al.,
2004). Wild-type HTT interacts with the molecular motor com-
plex that transports organelles along the microtubules in axons
(Gauthier et al., 2004; Caviston and Holzbaur, 2009). This interac-
tion is altered in HD, due to Exp-HTT expression,which decreases
axonal transport and the release of BDNF from cortical neurons
to their terminals within the striatum (Figure 1). This is thought
to participate in the striatal vulnerability in HD. One approach
FIGURE 1 | Altered striatal signaling pathways in HD. Afferent
corticostriatal and nigro-striatal projections modulate striatal signaling,
which is impaired in Huntington’s Disease (HD). Neurotrophic factor BDNF
release from cortical afferences is decreased in cortico-striatal synapses as
a consequence of Exp-HTT-mediated down-regulation of bdnf transcription
and axonal transport in cortical neurons. A shift from synaptic to
extrasynaptic NMDAR-dependent signaling participates to striatal neurons
to death. In a physiological condition, calcium inﬂux through synaptic
NMDAR promotes activation of the MAPkinase/ERK signaling pathway
along with its nuclear target, the MSK-1 protein, which phosphorylates the
transcription factor CREB. MSK-1 activation promotes chromatin
remodeling, which is crucial for CREB-mediated pgc-1α transcription, a key
gene involved in mitochondria biogenesis. Synaptic NMDARs also promote
formation of non-toxic Exp-HTT inclusion via TRIC. In HD, localization and
activity of extrasynaptic NMDAR are enhanced by Exp-HTT, which promotes
neuronal cell injury and death. The toxic effect of extrasynaptic NMDAR is
partly due to (i) the upregulation of Rhes expression that disaggregates the
non-toxic Exp-HTT inclusions (ii) to an impairment of mitochondrial
functions and (iii) to a decrease of the ERK/MSK-1/CREB signaling module
to the pgc-1α promoter. Dopamine release from nigro-striatal inputs
promotes oxidative stress via the production of reactive oxygen species
(ROS), which potentiates activation of the pro-apoptotic JNK pathway
induced by Exp-HTT. In addition, Dopamine potentiates Exp-HTT-mediated
striatal neurons death through activation of the Rho/ROCK signaling
pathway downstream D2R.
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to compensate for the defective BDNF transport is to mimic the
phosphorylation of Exp-HTT on Ser421, in order to restore the
interaction between Exp-HTT and dynactin, and their association
with microtubules (Colin et al., 2008). Interestingly, increasing
tubulin acetylation using a speciﬁc histone deacetylase (HDAC6)
inhibitor restores the recruitment of motor proteins, including
kinesin-1 and dynein to microtubules, and increases BDNF axonal
transport in cortical neurons (Dompierre et al., 2007).
Huntingtin is also involved in the trafﬁcking and secretion
of vesicles from the Golgi apparatus (Strehlow et al., 2007). In
particular, it promotes, acting in concert with transglutaminase 2
(TGase 2) and HJSJ1b, the budding of vesicles containing BDNF
from the Golgi to the cytoplasm (Borrell-Pages et al., 2006a; Del
Toro et al., 2006). Modulation of TGase 2 and HJSJ1b expres-
sion by cystamine or cysteamine increases the release of BDNF
in mice and monkey models of HD (Borrell-Pages et al., 2006b).
The trafﬁcking of neural proteins from the Golgi is also regulated
by HTT-interacting protein 14 (HIP14), which normally inter-
acts with HTT to regulate the trafﬁcking of neuronal proteins and
their synaptic release through palmitoylation of cysteine string
protein (CSP; Yanai et al., 2006; Ohyama et al., 2007). Finally, Exp-
HTT increases c-Jun-Kinase3 (JNK3) activity, which phosphory-
lates kinesin on Ser176 and reduces its binding to microtubules
(Morﬁni et al., 2009). Thus, inhibition of the neuron-speciﬁc JNK3
can also protect from defects in fast axonal transport induced by
Exp-HTT.
EXCITOTOXICITY AND STRIATAL SIGNALING
In HD, increased glutamate levels within the striatum are thought
to arise from reduction of glial glutamate uptake (Liévens et al.,
2001; Behrens et al., 2002). This is because of selective down-
regulation of the glutamate transporter GLT1, which is mainly
expressed in astrocytes. In Drosophila glia, Exp-HTT antagonize
epidermal growth factor receptor (EGFR)Ras-extracellular signal-
regulated kinase (ERK) signaling pathway, resulting in down-
regulation of the glutamate transporter levels (Liévens et al., 2006).
In addition, the expression of glutamine synthetase, an enzyme
that converts glutamate to glutamine in glia, was also found to
be altered (Liévens et al., 2001; Behrens et al., 2002). These ﬁnd-
ings demonstrated that the HD mutation results in a progressively
deranged glutamate handling in the brain, beginning before the
onset of symptoms in mice. They also provided evidence for a
contribution of excitotoxicity to the pathophysiology of HD.
NMDAR-MEDIATED EXCITOTOXICITY IN HD
Ineffective management of Ca2+ homeostasis by striatal neurons
ultimately leads to cell death via numerous signaling pathways.
This excitotoxicity mostly implicates the N -Methyl-d-Aspartate
type glutamate receptors (NMDAR) due to their high calcium
permeability and slow activation/deactivation kinetics (Rothman
and Olney, 1995; Dingledine et al., 1999; Cull-Candy et al., 2001).
The earliest evidence in support of a role for NMDAR-mediated
excitotoxicity in HD came from rodent studies where the admin-
istration of NMDAR agonists mimicked some clinical and patho-
logical features of the disease (Beal et al., 1986; Sanberg et al.,
1989; Ferrante et al., 1993). Studies have since switched from
these chemical HD models to genetic mouse models where the
expression of Exp-HTT protein has been linked to NMDAR-
mediated excitotoxicity (Levine et al., 1999; Cepeda et al., 2001;
Zeron et al., 2004). However, comparisons between HD models
are complicated as the mRNA and protein expression levels of the
NMDAR subunits vary between models and the disease state (Fan
et al., 2007). Furthermore, age-related dependence to excitotoxi-
city has been recently highlighted in the transgenic YAC128 HD
mice model, which display enhanced sensitivity to excitotoxicity
in the early phase of the disease, prior to development of cognitive
dysfunction andmotor abnormalities, and resistance to excitotoxic
stress as the disease progresses (Graham et al., 2009).
TARGETING NMDAR SUBUNITS
Pharmacological analyses have indicated that striatal NMDARs
are most commonly formed from heterotetramers containing two
obligatory NMDAR type 1 subunits (GluN1, previously known
as NR1) plus a combination of two NMDAR type 2 subunits,
GluN2A and GluN2B, as heterodimers or as heterotrimers (GluN1
plus GluN2A and GluN2B). Some literature points to NMDARs
containing principally GluN2A as being pro-survival whereas
GluN2B-containing NMDARs act as the excitotoxic mediators
(Zeron et al., 2002; Liu et al., 2007). As the expression of GluN2B
is signiﬁcantly higher than GluN2A in the striatum than in other
brain regions (Landwehrmeyer et al., 1995; Kuppenbender et al.,
2000), a GluN2B-mediated excitotoxicity is consistent with the
striatal vulnerability for neurodegeneration in HD. Interestingly,
recent work has demonstrated a greater contribution by GluN2A
containing NMDAR in the D1 expressing MSNs than D2 express-
ing MSNs which degenerate ﬁrst in HD (Jocoy et al., 2011). In
the YAC transgenic FVB/N mouse model of HD, NMDA-induced
cell death is prevented by a speciﬁc GluN2B antagonist ifenprodil
(Zeron et al., 2002). Likewise, doublemutantmice expressing Exp-
HTT and overexpressingGluN2B displayed an exacerbated striatal
degeneration (Heng et al., 2009). The logical conclusion from these
studies is that selective antagonists of GluN2B such as ifenprodil,
RO-25,6981, and CP101,606 should offer some neuroprotection.
However, the use of three different GluN2B antagonists had no
beneﬁcial effects in the R6/2 mouse model of HD (Tallaksen-
Greene et al., 2010). In addition, both ifenprodil and RO-25,6981
increase cell death induced by oxidative stress (Papadia et al.,
2008) and blockade of spontaneous GluN2B activity exacerbates
staurosporine-induced cell death (Martel et al., 2009). Therefore,
as the outcome depends on the considered model and the par-
ticular excitotoxic insult the argument is left open as to whether
GluN2B merits speciﬁc targeting in HD excitotoxicity.
GLUTAMATE RECEPTOR LOCALIZATION AND EXCITOTOXICITY
Instead of a deﬁnite GluN2B subunit-speciﬁc implication for exci-
totoxic signaling, work by Hardingham and Bading fueled the
hypothesis that activation of extrasynapticNMDAR (those located
at the cell body, dendritic shaft or on the neck of spines) promotes
cell death whereas stimulation of synaptic NMDAR promotes cell
survival (Hardingham and Bading, 2010). These hypotheses may
not be in complete opposition as extrasynaptic NMDAR contain
more GluN2B than synaptic ones (Tovar and Westbrook, 1999;
Steigerwald et al., 2000; Jocoy et al., 2011). Stimulation of cal-
cium entry via synaptic NMDAR is well tolerated and coupled to
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activation of the MAPkinase/ERK signaling pathway along with
its target the transcription factor cyclic AMP-response element
binding (CREB), which regulates genes such as bdnf (Hardingham
et al., 2001, 2002). On the other hand these pro-survival media-
tors are dominantly opposed by the activation of extrasynaptic
NMDAR which leads to the loss of mitochondrial membrane
potential, inhibition of ERK signaling, CREB shut off (Vanhoutte
and Bading, 2003), and an induction of a distinct genomic pro-
gram including the gene clca1a,which encodes a calcium-activated
chloride channel sufﬁcient to kill neurons (Zhang et al., 2007).
In HD, the striatal speciﬁc signaling partners of synaptic versus
extrasynaptic NMDAR have begun to be analyzed. Ras homolog
enriched in striatum (Rhes) is localized in the striatum, where it
speciﬁcally bind to Exp-HTT and elicits both a decrease in ubiqui-
tination and an increase in sumoylation of Exp-HTT, which leads
to its disaggregation and favors the formation of neurotoxic sol-
uble microaggregates (Subramaniam et al., 2009). Okamoto et al.
(2009) found that Rhes expression is reduced when extrasynaptic
receptors are blocked, whereas antagonism of synaptic NMDAR
leads to a decrease in Exp-HTT aggregates and cell death. This
study distinguished between the two receptor pools by the use of
the uncompetitive NMDAR antagonist memantine, which selec-
tively antagonizes extrasynaptic NMDAR at low concentrations
(Rammes et al., 2008). The formation of non-toxic Exp-HTT
inclusions is dependent on synaptic NMDAR activation and the
induction of the T-complex-1 (TCP-1) subunit of TCP-1 ring
complex (TRiC), which associates with heat shock protein 70
(Hsp 70) to favor the formation of these inclusions. By con-
trast, activation of extrasynaptic NMDAR in the presence of Exp-
HTT down-regulates the protective PPAR alpha-co-activator-1α
(PGC-1α) cascade (see below) via an inhibition of ERK activa-
tion and CREB phosphorylation (Okamoto et al., 2009). Inhibi-
tion of extrasynaptic NMDAR after in vivo treatment with a low
dose of memantine over a period of 8months increased TCP-
1 protein levels, inclusion formation, and improved the motor
function of YAC128 HD mice. By using the same approach, Mil-
nerwood et al. (2010) showed that a blockade of extrasynaptic
NMDAR restores basal levels of CREB activation and signiﬁcantly
overcomes motor learning deﬁcits of YAC128 mice. Even at pre-
symptomatic stages,YAC128mice expressmoreNMDAR subunits
at extrasynaptic sites than YAC18 control mice, and consequently
have a heightened response to glutamate spillover dependent on
an extrasynaptic GluN2B-containingNMDAR (Milnerwood et al.,
2010).
In addition to lateral NMDAR receptor localization, altered
NMDA receptor trafﬁcking may also participate to neuronal exci-
totoxicity in the striatum. Accelerated NMDA receptor trafﬁcking
and increased expression at the cell surface were found in stri-
atal neurons from the YAC72 HD mouse model (Fan et al., 2007).
This phenomenon can be related to an altered interaction between
Exp-HTT and postsynaptic density 95 (PSD-95), a scaffold pro-
tein necessary for NMDAR stability, which has been previously
described (Roche et al., 2001; Sun et al., 2001). Recently, associ-
ation of PSD-95 with GluN2B in striatal tissue has been shown
to be enhanced by Exp-HTT (Fan et al., 2009). Treatment of cul-
tured MSNs with a TAT coupled peptide that blocks binding of
GluN2Bwith PSD-95, reducesNMDAR surface expression in both
YAC transgenic and WT MSN and rescues cells from NMDAR
excitotoxicity.
TheHIP1,whichnormally interactswithHTT, is involved in the
intracellular trafﬁcking of glutamate receptors of the AMPA sub-
types. Exp-HTT, which interacts less efﬁciently with HIP1 than its
normal counterpart, participates to increased membranal expres-
sion of AMPA receptors and hence to excitotoxic neuronal death
in HD (Metzler et al., 2007). Altered calcium homeostasis in HD
could be due to an abnormal interaction between Exp-HTT and
the type 1 inositol 1,4,5-trisphosphate receptor (InsP3R1), which
regulates the cytoplasmic calcium clearance by the endoplasmic
reticulum (Tang et al., 2004, 2009). Disrupting the interaction
between InsP3R1 and Exp-HTT normalizes calcium signaling,
protects from glutamate-induced apoptosis in striatal neurons
in vitro, and reduces neuronal pathology and motor deﬁcits in
a mouse model of HD in vivo.
STRIATAL VULNERABILITY: THE DOPAMINERGIC
HYPOTHESIS
In addition to the glutamatergic stimulation, some evidence indi-
cate that Dopamine (DA) stimulation may play a key role in
excitotoxicity in HD (Reynolds et al., 1998; Charvin et al., 2005,
2008; Cyr et al., 2006; Stack et al., 2007; Tang et al., 2007; Benchoua
et al., 2008); Knock-out mice for the DA transporter (DAT) show
spontaneous striatal death accompanied by behavioral alterations
that resemble HD speciﬁcally during aging (Cyr et al., 2003). In an
elegant study, a double mutant mouse strain with both enhanced
dopamine transmission and endogenous expression of a mutant
HTT gene was generated. This strain was generated by crossing
the DAT knock-out mouse with a knock-in mouse model of HD
containing 92 CAG repeats (Cyr et al., 2006). These doublemutant
mice exhibited increased behavioral and neuropathological hall-
marks of HD, including neuropil aggregates in MSN projection
neurons. DA released from nigro-striatal inputs, is present in
high concentrations within the striatum and enhances sensitiv-
ity to glutamatergic inputs. It may also produce oxidative stress
via the production of reactive oxygen species (ROS), a cellular
process that increases with aging (Jakel and Maragos, 2000). In
particular, cultures of striatal neurons from R6/2 HD mice are
sensitized to DA-induced oxidative stress, leading to neuronal
autophagy (Petersen et al., 2001). ROS produced by low doses
of DA potentiate activation of the pro-apoptotic JNK pathway
induced by Exp-HTT (Garcia et al., 2004; Charvin et al., 2005),
the pharmacological inhibition of which is neuroprotective in the
R6/2 transgenic mouse model of HD (Apostol et al., 2008). DA
may also render striatal neurons more vulnerable to Exp-HTT
via dopamine receptor-mediated mechanisms (Charvin et al.,
2005, 2008). Depending on the cell line model of HD, express-
ing either the full length or truncated versions of Exp-HTT, D1,
or D2 receptors stimulation seems to be different. Full-length
Exp-HTT is required for alteration of calcium signaling (Zhang
et al., 2008). In striatal neurons from YAC128 transgenic or Q111
knock-in mice, both expressing full-length Exp-HTT, D1 recep-
tor stimulation potentiates calcium inﬂux via NMDA receptors,
and hence excitotoxic processes, including mitochondrial depo-
larization, and caspase activation (Cepeda et al., 2001; Zeron et al.,
2002, 2004; Starling et al., 2005; Tang et al., 2007). More recently, a
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calcium-dependent activation of calpain was shown to be involved
in striatal death after convergent activation of NMDA and D1
receptors in HD cell models (Paoletti et al., 2008). Increases in cal-
cium inﬂux lead to the cleavage of Cdk5 co-activator p35 into p25,
which enables an aberrant toxic activation of Cdk5 (Paoletti et al.,
2008). By contrast, when associated with p35 as a co-activator,
Cdk5 is known to be protective via phosphorylation of Exp-HTT
and the blockade of caspase-induced cleavage, resulting in attenu-
ated aggregate formation and toxicity (Luo et al., 2005; Anne et al.,
2007). Consistently, Cdk5/p35 suppresses the formation of aggre-
gates induced by a short fragment of Exp-HTT (exon 1), via a new,
unexpected role on microtubule stability and hence inclusion for-
mation (Kaminosono et al., 2008). Together, these data highlight
the complexity of Cdk5 activity and the importance of targeting
selectively p25 to block Exp-HTT-induced inclusion formation
and neuronal death.
A central role of DARPP-32 (Dopaminergic and cAMP-
regulated phosphoprotein) has also been proposed (Metzler et al.,
2010). DARPP-32 phosphorylation at Thr34 is induced by a D1
agonist (SKF 81297) and inhibits in turn the activity of PP1, a
phosphatase that dephosphorylates the Ser421 residue of the HTT
protein. Of interest, inhibition of PP1 can offer protection from
NMDA-induced excitotoxicity inYAC128 mice, through increased
phosphorylation of Ser421-HTT. The loss of DARPP-32 expres-
sion described inHD results in an increase of PP1 activity followed
by a decrease of Ser421-Exp-HTT phosphorylation (Metzler et al.,
2010). As its cleaved version, Exp-HTT is not sensitive to D1 ago-
nists, probably because it is not sensitive to calcium overload and
calcium-dependent proteolytic processes produced by D1 recep-
tor stimulation. By contrast, D2 receptors stimulation potentiates
Exp-HTT-induced aggregate formation, deﬁciency of mitochon-
drial complex II protein activity, and neuronal death (Charvin
et al., 2005; Benchoua et al., 2008). In vivo, in a rat model of
HD based on lentiviral-mediated expression of Exp-HTT exon 1
in the striatum (De Almeida et al., 2002), an early and chronic
treatment with the D2 antagonist, haloperidol decanoate, protects
striatal neurons from Exp-HTT-induced dysfunction, and aggre-
gates formation (Charvin et al., 2008). Striatal signaling mediated
by D2 receptor stimulation on Exp-HTT toxicity has been recently
elucidated. Inhibition of the Rho/ROCK pathway using selec-
tive inhibitors or knockdown of ROCK-II expression reversed
D2 agonist-mediated aggregate formation, neuritic retraction and
neuronal death induced by Exp-HTT (Deyts et al., 2009).
MITOCHONDRIAL DYSFUNCTION AND ENERGY DEFICITS
Defects in energy metabolism in brain and muscles, has long been
proposed to be involved in HD, from clinical (Djousse et al., 2002;
Hamilton et al., 2004) biochemical (Arenas et al., 1998; Turner
et al., 2007) and neuroimaging studies (Jenkins et al., 1998). In
HDpatients there is strong evidence for reduced glucose consump-
tion in the brain, more speciﬁcally in the basal ganglia (Grafton
et al., 1992; Kuwert et al., 1993) as well as increased lactate con-
centrations in the basal ganglia and occipital cortex (Jenkins et al.,
1993), and lactate-to-pyruvate levels in the CSF (Jenkins et al.,
1998). Various mechanisms that underlie the energy deﬁcit in the
HD brain have been proposed (Mochel et al., 2007; Mochel and
Haller, 2011). They include impaired oxidative phosphorylation,
oxidative stress, impairedmitochondrial calciumhandling, abnor-
mal mitochondria trafﬁcking, decreased glycolysis, and transcrip-
tional deregulation of PGC-1α. A deﬁciency of respiratory chain
complex II, i.e., succinate dehydrogenase (SDH), in HD has been
proposed since the observation that accidental ingestion of 3-
nitropropionic acid (3-NP), an irreversible inhibitor of SDH,
reproduces the clinical and neuropathological characteristics of
HD in humans (Brouillet et al., 1999). In rodents, systemic 3-NP
administration reproduces selective striatal degeneration, despite
an altered SDH activity in multiple brain regions (Brouillet et al.,
1998). Conversely, restoration of the complex II activity level is
neuroprotective in a cellular model of HD (Benchoua et al., 2006).
Activation of the pro-apoptotic JNK pathway is observed selec-
tively in striatal neurons of 3-NP-administered rats in vivo, and
overexpression of a dominant negative, non-phosphorylable ver-
sion of c-Jun in vitro inhibits striatal degeneration induced by
3-NP (Garcia et al., 2002). DA signaling regulates SDH enzymatic
activity (Benchoua et al., 2008) and hencemay account for the vul-
nerability of striatal neurons in HD. Furthermore, as detailed in
the next section Exp-HTT-induced transcriptional dysregulation
is now thought to contribute to altered bioenergetics.
TRANSCRIPTIONAL DYSREGULATION
Transcriptional dysregulation is an early event in the neuropatho-
logical process. Altered levels of dopaminergic receptor and neu-
ropeptide mRNAs observed in patient’s brain tissues (Augood
et al., 1996, 1997) are also observed in pre-symptomatic HD’s
transgenic mice, suggesting that changes in transcription underlie
neurodegeneration rather than reﬂecting non-speciﬁc degrada-
tion of all RNAs in affected neurons (Cha et al., 1998, 1999).
Subsequently, multiple genes encoding neurotransmitter recep-
tors, enzymes, and proteins involved in neuron structure, stress
responses, and axonal transport were found to be dysregulated
(Luthi-Carter et al., 2000, 2002; Sugars and Rubinsztein, 2003;
Cha, 2007; Runne et al., 2007), with overlaps of altered tran-
scripts between various mouse models of HD and brain of HD
patients (Kuhn et al., 2007). Interestingly, more than 80% of clas-
sically admitted striatal-enriched genes (genes with higher relative
expression in the striatum compared with other brain regions)
are decreased in a mouse model of HD as well as in human HD
postmortem brain (Desplats et al., 2006). A down-regulation of
novel striatal-enriched genes involved in vesicle transport and
trafﬁcking, tryptophan metabolism, and neuroinﬂammation were
identiﬁed more recently in both HD mouse striatum and caudate
from HD patients (Mazarei et al., 2010). Of interest, most of HD-
induced dysregulation of the striatal transcriptome can be largely
attributed to the intrinsic effects of mutant HTT, in the absence of
expression in cortical neurons (Thomas et al., 2011).
Transcriptional dysregulation can be found in large genomic
regions in a coordinated fashion and this dysregulation is associ-
ated with disease progression. Attempts were made to use tran-
scriptional dysregulation as a biomarker in HD. Genome-wide
expression proﬁling of the blood from HD’s patients revealed
signiﬁcant differences in symptomatic patients (Borovecki et al.,
2005), but not moderate-stage patients (Runne et al., 2007).
Thus, these biomarkers need to be further validated before their
widespread use in clinical trials.
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MOLECULAR MECHANISMS OF TRANSCRIPTIONAL DYSREGULATION
IN HD
Within the nucleus Exp-HTT,under its soluble or aggregated form,
interacts with and inhibits the activity of proteins involved in the
normal transcriptional machinery. These include TATA binding
protein (TBP), transcription factor II F (TFIIF), and tyrosine-
aminotransferase II (TATII) 130 (Shimohata et al., 2000; Suhr
et al., 2001; Dunah et al., 2002; Li et al., 2002). Exp-HTT also
sequesters transcription factors involved in cell viability, includ-
ing CREB protein (CBP), p53, speciﬁcity protein 1 (Sp1), nuclear
factor-kappa B (NF-κB), nuclear receptor co-repressor (NCoR),
and CA150 (Boutell et al., 1999; Li et al., 2000; Steffan et al., 2000;
Nucifora et al., 2001; Dunah et al., 2002; Bae et al., 2005; Arango
et al., 2006). Expression levels of BDNF, and its receptor TrkB,
are decreased in the striatum of HD patient’s, suggesting a deﬁcit
in cortical neurotrophic support of the striatum (Ferrer et al.,
2000; Zuccato et al., 2001; Lynch et al., 2007; Strand et al., 2007).
In animal models of HD, cortical BDNF expression is reduced
(Zuccato et al., 2001). Moreover, downregulating BDNF in stria-
tum in mice worsens the HD phenotype, whereas elevating BDNF
expression in the forebrain alleviates the HD phenotype (Canals
et al., 2004; Strand et al., 2007; Gharami et al., 2008; Xie et al.,
2010). The molecular mechanisms by which Exp-HTT drives the
down-regulation of BDNF expression in cortical neurons have
been unraveled. Wild-type HTT sequesters R element-1 silencing
transcription factor (REST), a transcriptional repressor of neu-
ronal survival factors including BDNF, within the cytoplasm. The
HTT mutation leads to REST release within the nucleus, where
it exerts a potent inhibitory role on the transcription of BDNF
and other neuronal genes (Zuccato et al., 2001, 2003, 2007). Fur-
thermore, REST mRNA levels are increased in R6/2 mouse model
of HD and NG108 neuronal-like model of HD. At the transcrip-
tional level, Sp1binds to the Sp factor binding sites contained in the
promoter of REST and contributes to Exp-HTT-mediated REST
upregulation (Ravache et al., 2010). BDNF expression is also a
component of the neuroprotective transcriptional response medi-
ated byNF-κB in neurons (Lipsky et al., 2001). In addition, the loss
of BDNF expression and low levels of NF-κB activity in neurons
could lead to impairments of cognitive functions (Kaltschmidt
et al., 2005; Meffert and Baltimore, 2005), a common feature of
neurodegenerative disorders such as HD.
A LINK BETWEEN TRANSCRIPTIONAL DYSREGULATION AND ENERGY
DEFICITS IN HD
A link between Exp-HTT-induced transcriptional dysregulation
and energy deﬁcits has been recently described. Exp-HTT binds
to the tumor suppression gene p53 more avidly than wild-type
HTT and has been reported to increase p53 protein levels, nuclear
localization and transcriptional activity in neuronal cultures and
transgenic mice (Bae et al., 2005). Augmented p53 activity medi-
ates mitochondrial membrane depolarization and decreases com-
plex IV activity, and p53 inhibition or genetic deletion ameliorates
these changes in a cell culture model. PGC-1α is a transcriptional
co-activator that regulates mitochondrial biogenesis and oxidative
phosphorylation (Cui et al., 2006; Weydt et al., 2006). A role of
PGC-1α in HD pathogenesis was suspected from the observation
of selective striatal lesions inPGC-1α knock-mice (Lin et al., 2004).
A direct link between CREB phosphorylation and transcriptional
regulation at the PGC-1α promoter has been observed in neuronal
cells (Cui et al., 2006). Impairment of the CREB/PGC-1α signal-
ing cascade by suppression of excitatory synaptic activity or by
stimulation of extracellular NMDA receptors increases the vulner-
ability of HD neuronal cells (Okamoto et al., 2009). Mitogen and
stress-activatedprotein kinase-1 (MSK-1),a nuclear protein kinase
activateddownstreamof ERK,was shown to control the expression
levels of PGC-1α via increased binding of phosphorylated-CREB
and Histone H3 at the promoter region of PGC-1α. Overexpres-
sion of MSK-1 was protective against Exp-HTT-induced striatal
dysfunctions in vitro (Roze et al., 2008) and in vivo (Martin et al.,
2011; Figure 1).
ACTING ON CHROMATIN REMODELING TO IMPROVE
TRANSCRIPTIONAL DYSREGULATION IN HD
Chromatin remodeling that underlies DNA decompaction was
ﬁrst described in dividing cells, but is also one of the prime events
of transcription in post-mitotic mature neurons (Taniura et al.,
2007). This “above the genome”molecular mechanism, also called
an epigenetic mechanism, gates DNA access, and hence transcrip-
tion. It is critically controlled by post-translational modiﬁcations
of histones (H2A and H2B, H3 and H4), a group of highly basic
proteins tightly linked to DNA. In particular, the methylation and
acetylation state of histones is closely linked to the regions of
transcriptional activity by regulating transcription factor access to
promoter regions in the DNA. Histone acetylation at a promoter
generally increases transcription and the enzymes that catalyze
these reactions are histone acetyltransferases (HATs). By contrast,
HDACs catalyze deacetylation. Exp-HTT interacts with CBP and
blocks its intrinsic HAT activity (Steffan et al., 2001). Administra-
tion of HDACs inhibitors, including SAHA, sodium butyrate, and
phenylbutyrate, has demonstrated their therapeutic role in sev-
eral HD models (Steffan et al., 2000; Ferrante et al., 2003; Hockly
et al., 2003; Gardian et al., 2005), as they improved behavioral
performance and neuronal survival. Interestingly, administration
of a new benzamide-type HDAC inhibitor with lower potential
toxicity than previous HDAC inhibitors, HDACi 4b, also restores
the transcription of critical striatal genes and improves motor and
neuropathological phenotype of R6/2 HD mice (Thomas et al.,
2008). All theseHDAC inhibitors act broadly across various classes
of HDACs (Lesort et al., 1999). Inhibitors targeting a speciﬁc class
of HDACs may result in a better beneﬁt to side effect ratio (Pal-
los et al., 2008). Finally, it must be emphasized that the levels of
acetylated histones are not decreased globally in HD mice models,
but rather selectively in the promoters of genes that are speciﬁcally
down-regulated in HD (Sadri-Vakili et al., 2007).
Methylation of histones plays the opposite, inhibitory role on
transcription. One of the proteins involved in methyltransferase
activity at histone H3 (K9) is ERG-associated protein with SET
domain (ESET). ESET expression is increased in HD patients and
R6/2 HD mice (Ryu et al., 2006). Sp1 acts as a transcriptional
activator of the ESET promoter at guanosine–cytosine (GC)-rich
DNA binding sites (Yang et al., 2003). Inhibiting Sp1 binding
to these sites using mitramycin (a clinically approved antitumor
antibiotic) suppressed basal ESET promoter activity in a dose-
dependent manner. The combined pharmacological treatment of
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mithramycin and cystamine, down-regulates ESET gene expres-
sion and hypertrimethylation of histone H3. This treatment
signiﬁcantly ameliorates the behavioral and neuropathological
phenotype of R6/2 HD mice and improves their survival. Owing
to its HEAT repeat α-solenoid structure, HTT acts as a facilitator
of the epigenetic silencer polycomb repressive complex 2 (PRC2;
Seong et al., 2010). The polyglutamine region augments PRC2
stimulation and hence H3 trimethylation on speciﬁc promoters,
includingHoxb9. In general, theDNA/RNAbinding agents anthra-
cyclines are thought to provide a signiﬁcant therapeutic potential
by correcting the pathological nucleosome changes and realigning
transcription. Two such agents, chromomycin and mithramycin,
were found to improve altered nucleosomal homeostasis, and by
virtue of normalizing the shift in the balance between methylation
and acetylation inHDmice, could alter a subset of down-regulated
genes accompanied by a signiﬁcant improvement of the behavioral
and neuropathological phenotype observed in HD mice (Stack
et al., 2007).
The transcriptional co-repressor transglutaminase 2 (TG2),
which is up-regulated in HD, interacts physically with Histone H3
and could contribute to gene silencing via hyperpolyamination of
histone tails (McConoughey et al., 2010). The inhibition of TG2
increases PGC-1α expression, but also that of 40% of genes that
are dysregulated (Karpuj et al., 1999; Lesort et al., 1999) inHD stri-
atal neurons. Histone H2A ubiquitinylation is increased in R6/2
HD mice and the association of ubiquitinylated H2A with the pro-
moters of down-regulated genes is increased in an in vitro model
of HD (Kim et al., 2008). This transcriptional repression is res-
cued by restoration of the ubiquitinylated H2A level. In addition,
histone H2B ubiquitinylation is decreased in R6/2 HD mice and
association of ubiquitinylated H2B with promoters positively cor-
relates with transcriptional level in R6/2 mice. This transcriptional
modulation by H2 ubiquitinylation is thought to occur through
a subsequent interference with methylation of histone H3 (Kim
et al., 2008).
Histone H3 phosphorylation is also critical to induce the
nucleosomal response and gene transcription at some promot-
ers. MSK-1 is critically involved in Histone H3 phosphorylation
in the striatum (Brami-Cherrier et al., 2005, 2009). It is deﬁ-
cient in the striatum of R6/2 mice and postmortem caudate of
HD patients (Roze et al., 2008). Restoring MSK-1 expression and
subsequent striatal H3 phosphorylation in an in vitro model
system of HD protects against neuronal alteration induced by the
Exp-HTT including neuritic retraction, aggregate formation, and
neuronal death (Roze et al., 2008). In vivo, in a rat model of HD
based on striatal lentiviral expression of Exp-HTT, overexpression
of MSK-1 induced hyperphosphorylation of H3 and CREB, along
with an overexpression of PGC-1α (Martin et al., 2011). Simi-
larly to PGC-1α, MSK-1 protects from Exp-HTT-induced striatal
dysfunctions, includingDARPP-32down-regulation andneuronal
death. Furthermore MSK-1 knock-out mice are more susceptible
to 3-NP-induced striatal lesion, and aging MSK-1 knock-out mice
show spontaneous striatal degeneration (Martin et al., 2011).
CONCLUSION
The regulation of neuronal death has been intensely investigated
and, due to its paramount implications for neurodegenerative dis-
ease, has sparked one of the most proliﬁc research ﬁelds in the past
decades. In particular, basic research has provided novel insights
into the molecular machinery of neuronal signaling, and how it
mediates neuronal dysfunction and death in progressive neurode-
generative diseases. HD involves a complex pathological cascade
with multiple deleterious mechanisms, affecting predominantly
the striatal neurons. This striatal vulnerability to HD-induced
neuronal dysfunction reﬂects both the particular characteristics of
striatal neurons (cell-autonomous alterations) and their location
within the functional neuronal networks (non-cell-autonomous
alterations). The various pathological events are not proceeding
in succession but instead take place in parallel with continu-
ous reciprocal interactions. This parallel and interactive nature
should be taken into account for both the general understand-
ing of the HD-related neurodegeneration and any therapeutic
approach.
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